BRIEF-Medicure receives response letter from FDA on Aggrastat SNDA for new indication

Thu Jul 7, 2016 7:31pm EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

July 7 (Reuters) - Medicure Inc

* Medicure receives response letter from FDA on aggrastat SNDA for new indication

* Received a complete response letter from U.S. Food and Drug Administration (FDA) for its supplemental new drug application

* FDA does not approve application in its present form Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)